Karyopharm Therapeutics Inc. Stock price

Equities

KPTI

US48576U1060

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 09:56:44 2024-03-28 am EDT 5-day change 1st Jan Change
1.495 USD +1.01% Intraday chart for Karyopharm Therapeutics Inc. +3.52% +69.94%
Sales 2024 * 147M Sales 2025 * 165M Capitalization 170M
Net income 2024 * -146M Net income 2025 * -182M EV / Sales 2024 * 1.67 x
Net Debt 2024 * 74M Net cash position 2025 * - EV / Sales 2025 * 1.03 x
P/E ratio 2024 *
-1.21 x
P/E ratio 2025 *
-1.41 x
Employees 325
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.94%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Karyopharm Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM
Transcript : Karyopharm Therapeutics Inc., Q4 2023 Earnings Call, Feb 29, 2024
Karyopharm Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Posts Q4 Revenue $33.7M, vs. Street Est of $33.6M MT
Karyopharm Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2024 CI
North American Morning Briefing : Fed's Preferred -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
Transcript : Karyopharm Therapeutics Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 02:15 PM
Karyopharm Therapeutics Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year 2023 CI
Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) dropped from NASDAQ Biotechnology Index CI
Karyopharm Therapeutics Says Phase 1 Study of Myelofibrosis Treatment Showed Spleen Volume Reduction Durability MT
Karyopharm Therapeutics Inc. Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi-Naive Myelofib) Patients CI
Karyopharm Therapeutics Inc. Announces Resignation of Peter K Honig as Member of the Board of Directors CI
RBC Cuts Price Target on Karyopharm Therapeutics to $3 From $4, Keeps Outperform Rating MT
More news
1 day+0.34%
1 week+3.52%
Current month+26.72%
1 month+10.53%
3 months+59.21%
6 months+7.30%
Current year+69.94%
More quotes
1 week
1.34
Extreme 1.34
1.51
1 month
1.11
Extreme 1.11
1.70
Current year
0.66
Extreme 0.6555
1.95
1 year
0.62
Extreme 0.6174
4.87
3 years
0.62
Extreme 0.6174
14.73
5 years
0.62
Extreme 0.6174
29.61
10 years
0.62
Extreme 0.6174
49.01
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 20-02-25
Director of Finance/CFO 49 19-02-24
Chief Tech/Sci/R&D Officer - 23-03-31
Members of the board TitleAgeSince
Director/Board Member 76 13-10-02
Director/Board Member 60 12-12-31
Director/Board Member 59 13-03-31
More insiders
Date Price Change Volume
24-03-28 1.49 +0.67% 51 957
24-03-27 1.48 +6.47% 1,301,235
24-03-26 1.39 0.00% 543,984
24-03-25 1.39 0.00% 581,779
24-03-22 1.39 -2.11% 792,757

Delayed Quote Nasdaq, March 28, 2024 at 09:41 am EDT

More quotes
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.48 USD
Average target price
5.571 USD
Spread / Average Target
+276.45%
Consensus
  1. Stock
  2. Equities
  3. Stock Karyopharm Therapeutics Inc. - Nasdaq